Organ-Specific MicroRNAs (MIR122, 137, and 206) Contribute to Tissue Characteristics and Carcinogenesis by Regulating Pyruvate Kinase M1/2 (PKM) Expression
Open Access
- 24 April 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (5) , 1276
Abstract
Pyruvate kinase is known as the glycolytic enzyme catalyzing the final step in glycolysis. In mammals, two different forms of it exist, i.e., pyruvate kinase M1/2 (PKM) and pyruvate kinase L/R (PKLR). Also, PKM has two isoforms, i.e., PKM1 and PKM2. These genes have tissue-specific distribution. Namely, PKM1 is distributed in high-energy-demanding organs, such as brain and muscle. Also, PKM2 is distributed in various other organs, such as the colon. On the other hand, PKLR is distributed in liver and red blood cells (RBCs). Interestingly, PKM2 has been recognized as one of the essential genes for the cancer-specific energy metabolism termed the “Warburg effect”. However, the mechanism(s) underlying this fact have remained largely unclear. Recently, we found that some organ-specific microRNAs (miRNAs, MIR) regulate PKM isoform expression through direct targeting of polypyrimidine tract binding protein 1 (PTBP1), which is the splicer responsible for PKM2-dominant expression. In this study, we examined whether this machinery was conserved in the case of other PTBP1- and PKM-targeting miRNAs. We focused on the MIRs 122, 137, and 206, and investigated the expression profiles of each of these miRNAs in tissues from mouse and human organs. Also, we examined the regulatory mechanisms of PKM isoform expression by testing each of these miRNAs in human cancer cell lines. Presently, we found that brain-specific MIR137 and muscle-specific MIR206 predominantly induced PKM1 expression through direct targeting of PTBP1. Also, liver-specific MIR122 suppressed the expression of both PKM1 and PKM2, which action occurred through direct targeting of PKM to enable the expression of PKLR. Moreover, the expression levels of these miRNAs were downregulated in cancer cells that had originated from these tissues, resulting in PKM2 dominance. Our results suggest that the organ-specific distribution of miRNAs is one of the principal means by which miRNA establishes characteristics of a tissue and that dysregulation of these miRNAs results in cancer development through a change in the ratio of PKM isoform expression. Also, our results contribute to cancer diagnosis and will be useful for cancer-specific therapy for the Warburg effect in the near future.Keywords
Funding Information
- JSPS KAKENHI (JP16H07344, JP15K10120)
This publication has 37 references indexed in Scilit:
- Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant propertiesOncogenesis, 2014
- MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesisJournal of Clinical Investigation, 2012
- Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exonsJournal of Molecular Cell Biology, 2011
- Turning on a Fuel Switch of Cancer: hnRNP Proteins Regulate Alternative Splicing of Pyruvate Kinase mRNACancer Research, 2010
- MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomasBritish Journal of Cancer, 2010
- Role of anti-oncomirs miR-143 and -145 in human colorectal tumorsCancer Gene Therapy, 2010
- The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolismProceedings of the National Academy of Sciences, 2010
- HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancerNature, 2009
- miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cellsBMC Medicine, 2008
- Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitroOncogene, 2007